2026 Q3 - tulosraportti
15 päivää sitten
‧41 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 44 | ||
| 524 | ||
| 170 | ||
| 18 | ||
| 34 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 päivä sitten · MuokattuThe company even openly admits that it was agreed with the underwriters that share prices should first be beaten down before setting the incredibly low price that the underwriters can get the share for at the expense of current shareholders. "Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters" Clip from https://www.affarsvarlden.se/artikel/bioinvents-nyemission-tre-flaggor-efter-kursslakten Emissionsguiden raises three flags. Large discount (initially) A large discount in a directed issue is a clear warning sign. But even in a rights issue, it shows great reluctance from underwriters and/or existing major shareholders to step up. The subscription price of 1 kr per share implies a discount of a staggering 73% against TERP. The discount is calculated on the ten-day volume-weighted average price before the company announced the issue. Bioinvent's Head of IR Cecilia Hofvander comments: "Since the issue was announced before the terms were known, the share price had already priced in the issue when the subscription price was set. A reference price based on 10-day VWAP before the initial announcement therefore yields a heavily exaggerated discount, as it is based on a price that no longer applied. Market practice is to measure the discount against the last traded price prior to the publication of the terms, and otherwise, apples are not compared with apples." When assessing a discount, Emissionsguiden always bases it on the date the companies notify the market of the upcoming issue. This also applies in cases where the terms are published only later, which Bioinvent did. Basing it on the later date would give these companies an advantage, as the assessment would then completely ignore the initial decline. High issue cost If one knows or has good reason to assume that the cost of advisors, underwriters, etc., eats up a large part of the issue proceeds, this is bad in several ways. However, the bar is set very differently depending on whether it is 10 MSEK or 1 billion to be raised. Bioinvent expects net proceeds of 366 MSEK, which implies issue costs of approximately 62 MSEK. This corresponds to 14.5% of the issue amount. In an issue of this size, that is high enough for a flag to be raised. Bioinvent refers to the fact that an underwriting fee of 12% is in line with comparable transactions, for example Orexo (13%) and Scandinavian Enviro (12%). Emissionsguiden's assessment, however, does not take into account what the costs consist of. Having to pay 62 MSEK to raise 428 MSEK is worth a flag, regardless of whether it is underwriters or something else driving up costs. The underwriting fee in Bioinvent's issue corresponds to approximately 42 MSEK. Messy issue process A messy process can indicate problems behind the scenes or poor planning. Examples of a messy issue process can be changed timetables, sudden management changes, late-entered investment commitments, or issue announcements without issue terms. Bioinvent announced the issue on October 28, but the final terms only arrived on November 5. Announcing an issue without a subscription price and other central terms leaves investors in uncertainty and often entails weak price performance. The share plummeted 72% on the first trading day after the issue announcement. Then it fell another 35% during the week when the market awaited the final terms. The underwriting commitments were expanded by 78 MSEK (an increase of 29%) when the issue terms were presented. The underwriting fee was simultaneously raised from 11 to 12% on the entire guarantee amount. Bioinvent also deviated from the original timetable. The terms were initially expected to be presented around November 25. Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters, so that the terms would reflect the share price taking into account the issue announcement when the shareholders make their decision. After the announcement, the market reacted and the board's assessment is that the information has been absorbed by the market, which enabled an earlier announcement of terms." The subscription period runs from December 7-21. Emissionsguiden will likely return with a new article around the time the company publishes its information document around December 2. Otherwise, the next article will be in connection with the outcome.
·9.11.As said, the share price will find its way up to around 6-7 kr before the date for trading in TR begins
Don't know what you are basing this on, but hope you are really right.
·8.11.For only 6 months ago the share price was 34ish and now the share price is at 2.49 and soon at price 1ish. It ought to almost be illegal to have such amateurish management. It takes a split second to lose credibility but on the other hand it takes a long time to rebuild. This issue can impossibly leave any sensible individuals who have faith in this management.- ·6.11.New price update from Redeye today after the announcement of the rights issue price: 8.6 SEK "At SEK1 per share, the rights issue adds about 430 million new shares to the current 65.8 million, taking the total to around 496 million. Shareholders who do not take part will see their holdings diluted by about 87%. Our fundamental value of SEK10 assumes full subscription in the rights issue. It includes pro forma net cash of about SEK605m, after issuing costs of around 12%. Our relative valuation is based on peer EV multiples, and it falls to about SEK3 per share. We weight the fundamental value at 80% and the relative value at 20%, which gives a fair value of SEK8.6, rounded to SEK9."Confirms to me once again that that stock should have been thrown out with the bathwater!
- ·6.11.I do not own the stock today, but can I subscribe for new shares at 1 DKK?
You can also skip buying TR and hope the issue is not fully subscribed, then you can apply for shares but it is not certain you will get any!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 193 896 | 193 896 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 193 896 | 193 896 | 0 | 0 |
2026 Q3 - tulosraportti
15 päivää sitten
‧41 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sitten · MuokattuThe company even openly admits that it was agreed with the underwriters that share prices should first be beaten down before setting the incredibly low price that the underwriters can get the share for at the expense of current shareholders. "Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters" Clip from https://www.affarsvarlden.se/artikel/bioinvents-nyemission-tre-flaggor-efter-kursslakten Emissionsguiden raises three flags. Large discount (initially) A large discount in a directed issue is a clear warning sign. But even in a rights issue, it shows great reluctance from underwriters and/or existing major shareholders to step up. The subscription price of 1 kr per share implies a discount of a staggering 73% against TERP. The discount is calculated on the ten-day volume-weighted average price before the company announced the issue. Bioinvent's Head of IR Cecilia Hofvander comments: "Since the issue was announced before the terms were known, the share price had already priced in the issue when the subscription price was set. A reference price based on 10-day VWAP before the initial announcement therefore yields a heavily exaggerated discount, as it is based on a price that no longer applied. Market practice is to measure the discount against the last traded price prior to the publication of the terms, and otherwise, apples are not compared with apples." When assessing a discount, Emissionsguiden always bases it on the date the companies notify the market of the upcoming issue. This also applies in cases where the terms are published only later, which Bioinvent did. Basing it on the later date would give these companies an advantage, as the assessment would then completely ignore the initial decline. High issue cost If one knows or has good reason to assume that the cost of advisors, underwriters, etc., eats up a large part of the issue proceeds, this is bad in several ways. However, the bar is set very differently depending on whether it is 10 MSEK or 1 billion to be raised. Bioinvent expects net proceeds of 366 MSEK, which implies issue costs of approximately 62 MSEK. This corresponds to 14.5% of the issue amount. In an issue of this size, that is high enough for a flag to be raised. Bioinvent refers to the fact that an underwriting fee of 12% is in line with comparable transactions, for example Orexo (13%) and Scandinavian Enviro (12%). Emissionsguiden's assessment, however, does not take into account what the costs consist of. Having to pay 62 MSEK to raise 428 MSEK is worth a flag, regardless of whether it is underwriters or something else driving up costs. The underwriting fee in Bioinvent's issue corresponds to approximately 42 MSEK. Messy issue process A messy process can indicate problems behind the scenes or poor planning. Examples of a messy issue process can be changed timetables, sudden management changes, late-entered investment commitments, or issue announcements without issue terms. Bioinvent announced the issue on October 28, but the final terms only arrived on November 5. Announcing an issue without a subscription price and other central terms leaves investors in uncertainty and often entails weak price performance. The share plummeted 72% on the first trading day after the issue announcement. Then it fell another 35% during the week when the market awaited the final terms. The underwriting commitments were expanded by 78 MSEK (an increase of 29%) when the issue terms were presented. The underwriting fee was simultaneously raised from 11 to 12% on the entire guarantee amount. Bioinvent also deviated from the original timetable. The terms were initially expected to be presented around November 25. Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters, so that the terms would reflect the share price taking into account the issue announcement when the shareholders make their decision. After the announcement, the market reacted and the board's assessment is that the information has been absorbed by the market, which enabled an earlier announcement of terms." The subscription period runs from December 7-21. Emissionsguiden will likely return with a new article around the time the company publishes its information document around December 2. Otherwise, the next article will be in connection with the outcome.
- ·9.11.As said, the share price will find its way up to around 6-7 kr before the date for trading in TR beginsDon't know what you are basing this on, but hope you are really right.
- ·8.11.For only 6 months ago the share price was 34ish and now the share price is at 2.49 and soon at price 1ish. It ought to almost be illegal to have such amateurish management. It takes a split second to lose credibility but on the other hand it takes a long time to rebuild. This issue can impossibly leave any sensible individuals who have faith in this management.
- ·6.11.New price update from Redeye today after the announcement of the rights issue price: 8.6 SEK "At SEK1 per share, the rights issue adds about 430 million new shares to the current 65.8 million, taking the total to around 496 million. Shareholders who do not take part will see their holdings diluted by about 87%. Our fundamental value of SEK10 assumes full subscription in the rights issue. It includes pro forma net cash of about SEK605m, after issuing costs of around 12%. Our relative valuation is based on peer EV multiples, and it falls to about SEK3 per share. We weight the fundamental value at 80% and the relative value at 20%, which gives a fair value of SEK8.6, rounded to SEK9."Confirms to me once again that that stock should have been thrown out with the bathwater!
- ·6.11.I do not own the stock today, but can I subscribe for new shares at 1 DKK?You can also skip buying TR and hope the issue is not fully subscribed, then you can apply for shares but it is not certain you will get any!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 44 | ||
| 524 | ||
| 170 | ||
| 18 | ||
| 34 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 193 896 | 193 896 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 193 896 | 193 896 | 0 | 0 |
2026 Q3 - tulosraportti
15 päivää sitten
‧41 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 25.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 29.10. | ||
2026 Q2 - tulosraportti 27.8. | ||
2026 Q1 - tulosraportti 29.4. | ||
2025 Q4 - tulosraportti 26.2. | ||
2025 Q3 - tulosraportti 29.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sitten · MuokattuThe company even openly admits that it was agreed with the underwriters that share prices should first be beaten down before setting the incredibly low price that the underwriters can get the share for at the expense of current shareholders. "Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters" Clip from https://www.affarsvarlden.se/artikel/bioinvents-nyemission-tre-flaggor-efter-kursslakten Emissionsguiden raises three flags. Large discount (initially) A large discount in a directed issue is a clear warning sign. But even in a rights issue, it shows great reluctance from underwriters and/or existing major shareholders to step up. The subscription price of 1 kr per share implies a discount of a staggering 73% against TERP. The discount is calculated on the ten-day volume-weighted average price before the company announced the issue. Bioinvent's Head of IR Cecilia Hofvander comments: "Since the issue was announced before the terms were known, the share price had already priced in the issue when the subscription price was set. A reference price based on 10-day VWAP before the initial announcement therefore yields a heavily exaggerated discount, as it is based on a price that no longer applied. Market practice is to measure the discount against the last traded price prior to the publication of the terms, and otherwise, apples are not compared with apples." When assessing a discount, Emissionsguiden always bases it on the date the companies notify the market of the upcoming issue. This also applies in cases where the terms are published only later, which Bioinvent did. Basing it on the later date would give these companies an advantage, as the assessment would then completely ignore the initial decline. High issue cost If one knows or has good reason to assume that the cost of advisors, underwriters, etc., eats up a large part of the issue proceeds, this is bad in several ways. However, the bar is set very differently depending on whether it is 10 MSEK or 1 billion to be raised. Bioinvent expects net proceeds of 366 MSEK, which implies issue costs of approximately 62 MSEK. This corresponds to 14.5% of the issue amount. In an issue of this size, that is high enough for a flag to be raised. Bioinvent refers to the fact that an underwriting fee of 12% is in line with comparable transactions, for example Orexo (13%) and Scandinavian Enviro (12%). Emissionsguiden's assessment, however, does not take into account what the costs consist of. Having to pay 62 MSEK to raise 428 MSEK is worth a flag, regardless of whether it is underwriters or something else driving up costs. The underwriting fee in Bioinvent's issue corresponds to approximately 42 MSEK. Messy issue process A messy process can indicate problems behind the scenes or poor planning. Examples of a messy issue process can be changed timetables, sudden management changes, late-entered investment commitments, or issue announcements without issue terms. Bioinvent announced the issue on October 28, but the final terms only arrived on November 5. Announcing an issue without a subscription price and other central terms leaves investors in uncertainty and often entails weak price performance. The share plummeted 72% on the first trading day after the issue announcement. Then it fell another 35% during the week when the market awaited the final terms. The underwriting commitments were expanded by 78 MSEK (an increase of 29%) when the issue terms were presented. The underwriting fee was simultaneously raised from 11 to 12% on the entire guarantee amount. Bioinvent also deviated from the original timetable. The terms were initially expected to be presented around November 25. Cecilia Hofvander comments: "We understand that the issue announcement without final terms created uncertainty and that the share price was affected. The setup was a conscious choice negotiated with the underwriters, so that the terms would reflect the share price taking into account the issue announcement when the shareholders make their decision. After the announcement, the market reacted and the board's assessment is that the information has been absorbed by the market, which enabled an earlier announcement of terms." The subscription period runs from December 7-21. Emissionsguiden will likely return with a new article around the time the company publishes its information document around December 2. Otherwise, the next article will be in connection with the outcome.
- ·9.11.As said, the share price will find its way up to around 6-7 kr before the date for trading in TR beginsDon't know what you are basing this on, but hope you are really right.
- ·8.11.For only 6 months ago the share price was 34ish and now the share price is at 2.49 and soon at price 1ish. It ought to almost be illegal to have such amateurish management. It takes a split second to lose credibility but on the other hand it takes a long time to rebuild. This issue can impossibly leave any sensible individuals who have faith in this management.
- ·6.11.New price update from Redeye today after the announcement of the rights issue price: 8.6 SEK "At SEK1 per share, the rights issue adds about 430 million new shares to the current 65.8 million, taking the total to around 496 million. Shareholders who do not take part will see their holdings diluted by about 87%. Our fundamental value of SEK10 assumes full subscription in the rights issue. It includes pro forma net cash of about SEK605m, after issuing costs of around 12%. Our relative valuation is based on peer EV multiples, and it falls to about SEK3 per share. We weight the fundamental value at 80% and the relative value at 20%, which gives a fair value of SEK8.6, rounded to SEK9."Confirms to me once again that that stock should have been thrown out with the bathwater!
- ·6.11.I do not own the stock today, but can I subscribe for new shares at 1 DKK?You can also skip buying TR and hope the issue is not fully subscribed, then you can apply for shares but it is not certain you will get any!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 44 | ||
| 524 | ||
| 170 | ||
| 18 | ||
| 34 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 193 896 | 193 896 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 193 896 | 193 896 | 0 | 0 |